- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05128591
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
February 20, 2022 updated by: Addpharma Inc.
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover, Phase 1 Study Under Fed State to Evaluate the Safety and Pharmacokinetics of AD-109 in Healthy Male Volunteers
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-109 in healthy male subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety profiles of AD-109 compared with AD-1091 in healthy male subjects.
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- H+ Yangji Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- The Age equal to or greater than 19 in healthy male volunteers at the time of screening visit
Exclusion Criteria:
- Patients with Medical history increasing the risk of bleeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A-Rivaroxaban
Period 1 : Reference Drug(AD-1091) Period 2 : Test Drug(AD-109)
|
AD-109 (Rivaroxaban 18mg) Oral Tablet
AD-1091 (Rivaroxaban 20mg) Oral Tablet
|
Experimental: Arm B-Rivaroxaban
Period 1 : Test Drug(AD-109) Period 2 : Reference Drug(AD-1091
|
AD-109 (Rivaroxaban 18mg) Oral Tablet
AD-1091 (Rivaroxaban 20mg) Oral Tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Plasma Concentration (Cmax)
Time Frame: pre-dose to 34 hours
|
Cmax of Rivaroxaban
|
pre-dose to 34 hours
|
Area Under the Curve in time plot (AUCt)
Time Frame: pre-dose to 34 hours
|
AUCt of Rivaroxaban
|
pre-dose to 34 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2021
Primary Completion (Actual)
December 31, 2021
Study Completion (Actual)
December 31, 2021
Study Registration Dates
First Submitted
November 10, 2021
First Submitted That Met QC Criteria
November 10, 2021
First Posted (Actual)
November 22, 2021
Study Record Updates
Last Update Posted (Actual)
March 8, 2022
Last Update Submitted That Met QC Criteria
February 20, 2022
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AD-109BE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Embolism and Thrombosis
-
The First Affiliated Hospital of Soochow UniversityNational Natural Science Foundation of ChinaUnknownThrombosis Embolism
-
Azienda Sanitaria ULSS 13 Dolo, MiranoUnknownEmbolism and Thrombosis of the Radial ArteryItaly
-
British Thoracic SocietyCompletedDeep Vein Thrombosis | Pulmonary Embolism | Deep Vein Thrombosis With Pulmonary EmbolismUnited Kingdom
-
Diagnostica Stago R&DHopital Lariboisière; Hôpital Louis MourierCompletedDeep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)France
-
Rennes University HospitalSFMV (French Society of Vascular Medicine)UnknownVenous Thrombosis or Pulmonary EmbolismFrance
-
Hamilton Health Sciences CorporationCanadian Institutes of Health Research (CIHR)TerminatedDeep Venous Thrombosis | Suspected Pulmonary EmbolismCanada
-
Heart and Vascular Outcomes Research InstituteUnknownVenous Thromboembolism, | Pulmonary Embolism, | Deep Vein Thrombosis,
-
Hellenic Society of Medical OncologyUnknownDeep Vein Thrombosis | Pulmonary Embolism | Vena Cava Thrombosis | Iliac; ThrombosisGreece
-
BayerJanssen Research & Development, LLCCompletedDeep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates
-
Scott C. Woller, MDJanssen PharmaceuticalsNot yet recruitingDeep Vein Thrombosis | Hospitalism | Venous Thromboembolic Disease | Pulmonary Embolism and ThrombosisUnited States
Clinical Trials on Rivaroxaban 18mg Oral Tablet
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy SubjectsChina
-
Herlev and Gentofte HospitalDanish Society of CardiologyRecruitingDeep Vein Thrombosis | Pulmonary EmbolismDenmark
-
Herlev and Gentofte HospitalDanish Society of CardiologyRecruitingAtrial Fibrillation | Atrial FlutterDenmark
-
Peshawar Institute of CardiologyGetz PharmaRecruitingLeft Ventricular ThrombusPakistan
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
University Hospital Inselspital, BerneCentre Hospitalier Universitaire VaudoisRecruitingLiver CirrhosisSwitzerland
-
Swiss Paraplegic Centre NottwilWithdrawnThromboembolism | Spinal Cord InjuriesSwitzerland
-
BayerCompleted
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States